Scarica l'app Stockscreener
3.02
3.07%
0.09
Dopo l'orario di chiusura:
3.05
0.03
+0.99%
Precedente Chiudi:
$2.93
Aprire:
$2.9
Volume 24 ore:
53,217
Relative Volume:
0.46
Capitalizzazione di mercato:
$142.34M
Reddito:
$18.11M
Utile/perdita netta:
$-18.95M
Rapporto P/E:
-6.9029
EPS:
-0.4375
Flusso di cassa netto:
-
1 W Prestazione:
-2.74%
1M Prestazione:
+18.90%
6M Prestazione:
+37.27%
1 anno Prestazione:
+47.32%
Intervallo 1D:
$2.80
$3.035
Intervallo di 1 settimana:
$2.7801
$3.20
Portata 52W:
$1.30
$3.53
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.02 | 138.09M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Guggenheim | Buy |
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2025-01-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Iniziato | China Renaissance | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 24.5% in February - MarketBeat
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk - MarketBeat
Comparing KALA BIO (NASDAQ:KALA) and Adagene (NASDAQ:ADAG) - Defense World
Adagene to Participate in Two Upcoming Investor Conferences - The Manila Times
Adagene sets Oppenheimer, Leerink fireside chats for Feb. 25, March 9 - Stock Titan
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - TradingView
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 283.2% - Defense World
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 283.2% - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 31.1% - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Adagene Provides Business Update and 2026 Objectives - The Manila Times
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 48.9% - MarketBeat
Total debt per share of Adagene, Inc. Sponsored ADR – LS:A2QN45 - TradingView — Track All Markets
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Declines By 36.8% - MarketBeat
Analysts Set Expectations for Adagene FY2025 Earnings - Defense World
Analysts Issue Forecasts for Adagene FY2025 Earnings - MarketBeat
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - The Globe and Mail
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Adagene stock soars after FDA grants Fast Track status for cancer therapy - Investing.com Nigeria
Adagene stock soars after FDA grants Fast Track status for cancer therapy By Investing.com - Investing.com South Africa
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer - Investing.com
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer By Investing.com - Investing.com South Africa
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewswire
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives $7.67 Consensus Target Price from Analysts - Defense World
Adagene (NASDAQ:ADAG) Earns Buy Rating from Analysts at Guggenheim - Defense World
Adagene (NASDAQ:ADAG) Now Covered by Guggenheim - MarketBeat
Get in on Adagene Inc ADR’s (ADAG) buy-in window today! - Setenews
Can Adagene Inc. Depositary Receipt stock double in next 5 years2025 Price Action Summary & Weekly Consistent Profit Watchlists - newser.com
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives $7.00 Average Target Price from Analysts - Defense World
Adagene (NASDAQ:ADAG) Upgraded at Lifesci Capital - Defense World
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - wahanariau.com
Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development - TipRanks
Adagene Inc. Announces Licensing Agreement with Third Arc Bio to Utilize SAFEbody Technology for CD3 T Cell Engagers - Quiver Quantitative
Adagene Announces Licensing Agreement with Third Arc Bio - GlobeNewswire
Why Adagene Inc. Depositary Receipt stock is in analyst buy zoneTrade Performance Summary & Weekly High Potential Alerts - newser.com
Why Adagene Inc. Depositary Receipt stock is a must watch in 2025Weekly Loss Report & Reliable Trade Execution Plans - newser.com
What’s the recovery path for long term holders of Adagene Inc. Depositary ReceiptExit Point & High Win Rate Trade Alerts - newser.com
Adagene Inc. Depositary Receipt stock daily chart insightsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Understanding Adagene Inc. Depositary Receipt’s price movement2025 Market Outlook & Community Supported Trade Ideas - newser.com
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC - Investing.com India
[F-3] Adagene Inc. Foreign Issuer Shelf Registration | ADAG SEC FilingForm F-3 - Stock Titan
Adagene Inc Adr Azioni (ADAG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):